These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 2853972

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
    Fernandes DJ, Danks MK, Beck WT.
    Biochemistry; 1990 May 01; 29(17):4235-41. PubMed ID: 2163274
    [Abstract] [Full Text] [Related]

  • 3. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S, Austin CA, Fisher LM.
    Anticancer Drug Des; 1990 Feb 01; 5(1):149-57. PubMed ID: 2156515
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS, Danks MK, Schmidt CA, Beck WT.
    Cancer Res; 1989 May 01; 49(9):2422-6. PubMed ID: 2539902
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M, Beck WT.
    Cancer Res; 1993 Dec 15; 53(24):5946-53. PubMed ID: 8261408
    [Abstract] [Full Text] [Related]

  • 8. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
    Wolverton JS, Danks MK, Granzen B, Beck WT.
    Cancer Res; 1992 Aug 01; 52(15):4248-53. PubMed ID: 1322239
    [Abstract] [Full Text] [Related]

  • 9. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
    Kim R, Beck WT.
    Cancer Res; 1994 Sep 15; 54(18):4958-66. PubMed ID: 8069863
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M, Blick M.
    J Biol Chem; 1989 Oct 05; 264(28):16411-20. PubMed ID: 2550442
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J, Catapano CV, Fernandes DJ.
    Biochemistry; 1996 Dec 17; 35(50):16354-60. PubMed ID: 8973211
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M, Chan D, Andersson BS, Beran M, Silberman L, Estey E, Ricketts L, Zwelling LA.
    Biochem Pharmacol; 1987 Dec 01; 36(23):4067-77. PubMed ID: 2825713
    [Abstract] [Full Text] [Related]

  • 17. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
    Taki T, Ohnishi T, Arita N, Hiraga S, Hayakawa T.
    J Neurooncol; 1998 Jan 01; 36(1):41-53. PubMed ID: 9525824
    [Abstract] [Full Text] [Related]

  • 18. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE, Cadena RS, Raimondi SC, Beck WT.
    Mol Pharmacol; 2000 Feb 01; 57(2):296-307. PubMed ID: 10648639
    [Abstract] [Full Text] [Related]

  • 19. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH.
    Hiroshima J Med Sci; 1989 Dec 01; 38(4):197-207. PubMed ID: 2561562
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.